Disease Markers

Research Article

Correlation between miR-200 Family Overexpression and Cancer Prognosis

Table 2

MicroRNA evaluation and survival data of the selected studies.


First author	Year	Country	Test method	Cancer type	MicroRNA	Sample source	Outcome	(95% CI)	Cut-off value

Zou J.	2017	China	RT-PCR	EOC	miR-429	Tissue	OS	(U) 0.641 (0.412–0.996)/(M) 0.763 (0.458–1.270)	>0.532
Zou J.	2017	China	RT-PCR	EOC	miR-429	Tissue	PFS	(U) 0.661 (0.478–0.915)/(M) 0.710 (0.504–1.001)	>0.532

Han Y.	2017	China	RT-PCR	CRC	miR-429	Tissue	OS	(M) 1.852 (1.019–3.326)	Median

Maierthaler M.-1	2017	Germany	TaqMan	CRC	miR-200a	Blood	OS	(U) 0.929 (0.707–1.211)/(M) 1.053 (0.791–1.401)	Median
Maierthaler M.-1	2017	Germany	TaqMan	CRC	miR-200b	Blood	OS	(U) 0.704 (0.524–0.945)/(M) 0.772 (0.570–1.045)
Maierthaler M.-1	2017	Germany	TaqMan	CRC	miR-200c	Blood	OS	(U) 0.808 (0.646–1.010)/(M) 0.840 (0.659–1.070)
Maierthaler M.-1	2017	Germany	TaqMan	CRC	miR-141	Blood	OS	(U) 0.925 (0.713–1.200)/(M) 1.038 (0.785–1.374)
Maierthaler M.-1	2017	Germany	TaqMan	CRC	miR-429	Blood	OS	(U) 0.951 (0.734–1.235)/(M) 0.968 (0.721–1.300)
Maierthaler M.-2	2017	Germany	TaqMan	CRC	miR-200a	Blood	OS	(U) 1.198 (0.986–1.456)/(M) 1.227 (1.008–1.495)
Maierthaler M.-2	2017	Germany	TaqMan	CRC	miR-200b	Blood	OS	(U) 1.172 (0.946–1.453)/(M) 1.208 (0.975–1.497)
Maierthaler M.-2	2017	Germany	TaqMan	CRC	miR-200c	Blood	OS	(U) 1.117 (0.947–1.318)/(M) 1.152 (0.975–1.362)
Maierthaler M.-2	2017	Germany	TaqMan	CRC	miR-141	Blood	OS	(U) 1.071 (0.877–1.305)/(M) 1.105 (0.904–1.350)
Maierthaler M.-2	2017	Germany	TaqMan	CRC	miR-429	Blood	OS	(U) 1.010 (0.853–1.196)/(M) 1.006 (0.845–1.198)
Maierthaler M.-1	2017	Germany	TaqMan	CRC	miR-200a	Blood	RFS	(U) 0.929 (0.718–1.203)/(M) 1.031 (0.786–1.353)
Maierthaler M.-1	2017	Germany	TaqMan	CRC	miR-200b	Blood	RFS	(U) 0.714 (0.539–0.947)/(M) 0.750 (0.561–1.005)
Maierthaler M.-1	2017	Germany	TaqMan	CRC	miR-200c	Blood	RFS	(U) 0.819 (0.657–1.019)/(M) 0.835 (0.658–1.060)
Maierthaler M.-1	2017	Germany	TaqMan	CRC	miR-141	Blood	RFS	(U) 0.910 (0.705–1.175)/(M) 0.999 (0.760–1.312)
Maierthaler M.-1	2017	Germany	TaqMan	CRC	miR-429	Blood	RFS	(U) 0.954 (0.743–1.227)/(M) 1.076 (0.716–1.618)
Maierthaler M.-2	2017	Germany	TaqMan	CRC	miR-200a	Blood	RFS	(U) 1.175 (0.973–1.420)/(M) 1.200 (0.989–1.456)
Maierthaler M.-2	2017	Germany	TaqMan	CRC	miR-200b	Blood	RFS	(U) 1.109 (0.893–1.377)/(M) 1.143 (0.919–1.422)
Maierthaler M.-2	2017	Germany	TaqMan	CRC	miR-200c	Blood	RFS	(U) 1.076 (0.911–1.272)/(M) 1.100 (0.930–1.302)
Maierthaler M.-2	2017	Germany	TaqMan	CRC	miR-141	Blood	RFS	(U) 1.057 (0.871–1.284)/(M) 1.085 (0.890–1.321)
Maierthaler M.-2	2017	Germany	TaqMan	CRC	miR-429	Blood	RFS	(U) 1.080 (0.916–1.272)/(M) 1.078 (0.910–1.277)

Si L.	2017	China	RT-PCR	NSCLC	miR-200c	Tissue	OS	(M) 2.095 (1.241–3.536)	The 2−ΔΔCq
Si L.	2017	China	RT-PCR	NSCLC	miR-200c	Tissue	DFS	(M) 1.647 (1.049–2.585)	The 2−ΔΔCq

Meng X.	2016	Germany	RT-PCR	EOC	miR-200a	Blood	OS	(U) 1.7 (0.8–3.5)	Median
Meng X.	2016	Germany	RT-PCR	EOC	miR-200b	Blood	OS	(U) 2.7 (1.3–5.7)/(M) 2.8 (1.1–6.8)
Meng X.	2016	Germany	RT-PCR	EOC	miR-200c	Blood	OS	(U) 2.4 (1.2–4.9)/(M) 2.5 (1.1–6.1)
Meng X.	2016	Germany	RT-PCR	EOC	miR-200a	Blood	RFS	(U) 1.1 (0.6–1.9)
Meng X.	2016	Germany	RT-PCR	EOC	miR-200b	Blood	RFS	(U) 1.6 (0.9–2.8)
Meng X	2016	Germany	RT-PCR	EOC	miR-200c	Blood	RFS	(U) 2.0 (1.1–3.6)/(M) 1.7 (0.8–3.6)

Dong S. J.	2016	China	RT-PCR	CRC	miR-429	Tissue	OS	(M) 2.296 (1.105–4.528)	Median

Antolín S.	2015	Spain	RT-PCR	BC	miR-200c	Blood	OS	(U) 1.38 (1.11–1.71)/(M) 2.79 (1.01–7.7)	>1.29 relative expression value
Antolín S.	2015	Spain	RT-PCR	BC	miR-200c	Blood	PFS	(U) 1.37 (1.09–1.71)/(M) 3.33 (1.22–9.07)
Antolín S.	2015	Spain	RT-PCR	BC	miR-141	Blood	OS	(M) 0.986 (0.942–1.032)
Antolín S.	2015	Spain	RT-PCR	BC	miR-141	Blood	PFS	(M) 0.987 (0.95–1.025)

Gao Y. C.	2015	China	RT-PCR	EOC	miR-200c	Blood	OS	(U) 3.14 (1.67–5.93)	−ΔCt method with 95% CI
Gao Y. C.	2015	China	RT-PCR	EOC	miR-141	Blood	OS	(U) 1.83 (1.00–3.33)	−ΔCt method with 95% CI

Lu Y. B.	2015	China	RT-PCR	GC	miR-141	Tissue	OS	(M) 2.972 (1.297–10.001)	Median

Liu J. Y.	2015	China	RT-PCR	EOC	miR-200a	Tissue	OS	(M) 0.354 (0.149–0.840)	Log 2−ΔΔCt
Liu J. Y.	2015	China	RT-PCR	EOC	miR-200a	Tissue	PFS	(M) 0.395 (0.210–0.742)	Log 2−ΔΔCt

Cao Q	2014	China	ISH	EOC	miR-200a	Tissue	OS	(U) 22.69 (1.32–50.53)/(M) 17.26 (1.36–36.98)	Median
Cao Q.	2014	China	ISH	EOC	miR-200b	Tissue	OS	(U) 20.28 (1.20–42.28)/(M)15.41 (1.13–31.36)
Cao Q.	2014	China	ISH	EOC	miR-200c	Tissue	OS	(U) 21.42 (1.26–48.33)/(M) 16.22 (1.27–33.81)

Kim M. K.	2014	Korea	RT-PCR	NSCLC	miR-200c	FFPE	OS	(M) 3.67 (1.17–11.45)	Median

Zhu W.-1	2014	China	RT-PCR	NSCLC	miR-429	Tissue	OS	(U) 1.686 (0.570–4.984)/(M) 2.749 (0.706–10.707)	Mean
Zhu W.-2	2014	China	RT-PCR	NSCLC	miR-429	Blood	OS	(U) 6.458 (1.409–29.593)/(M) 12.875 (2.295–72.23)	Mean

Song F.	2014	China	RT-PCR	GC	miR-200a	TMA	OS	(U) 0.82 (0.57–1.20)/(M) 0.72 (0.47–1.13)	Median
Song F.	2014	China	RT-PCR	GC	miR-200b	TMA	OS	(U) 0.87 (0.60–1.26)/(M)0.93 (0.63–1.41)
Song F.	2014	China	RT-PCR	GC	miR-200c	TMA	OS	(U) 1.19 (0.80–1.77)/(M) 1.32 (0.82–2.12)
Song F.	2014	China	RT-PCR	GC	miR-200a	TMA	DFS	(U) 0.81 (0.58–1.14)/(M) 0.67 (0.45–0.99)
Song F.	2014	China	RT-PCR	GC	miR-200b	TMA	DFS	(U) 0.84 (0.60–1.18)/(M) 0.82 (0.56–1.19)
Song F.	2014	China	RT-PCR	GC	miR-200c	TMA	DFS	(U) 1.08 (0.76–1.54)/(M) 1.06 (0.70–1.60)

Tejero R.-1	2014	Spain	TaqMan	NSCLC	miR-200c/141	FFPE	OS	(M) 2.787 (1.087–7.148)	Mean
Tejero R.-2	2014	Spain	TaqMan	NSCLC	miR-200c/141	FFPE	OS	(M) 10.649 (2.433–46.608)	Mean

Toiyama Y.-1	2014	Japan	RT-PCR	CRC	miR-200c	Blood	OS	(U) 2.43 (1.26–4.68)/(M)2.67 (1.28–5.67)	Median
Toiyama Y.-2	2014	Japan	RT-PCR	CRC	miR-200c	FFPE	OS	(U) 0.56 (0.28–1.10)	Median

Sun Q.	2014	China	RT-PCR	EOC	miR-200a	TMA	OS	(U) 0.58 (0.08–4.05)	Median (≥12.623)

Liu X. G.	2012	China	RT-PCR	NSCLC	miR-200c	Tissue	OS	(U) 6.020 (1.344–26.971)	2−ΔΔCt > 2.0
Liu X. G.	2012	China	RT-PCR	NSCLC	miR-141	Tissue	OS	(U) 4.135 (0.467–36.597)	2−ΔΔCt > 2.0
Chao A.	2012	China	RT-PCR	EOC	miR-200a	FFPE	OS	(M) 1.466 (0.786–2.734)	Log ratio > 1.3
Chao A.	2012	China	RT-PCR	EOC	miR-200a	FFPE	RFS	(M) 1.213 (0.70–2.101)	Log ratio > 1.3

Marchini S.	2011	Italy	RT-PCR	EOC	miR-200b	Tissue	OS	(U) 2.137 (0.801–5.701)/(M) 2.051 (0.640–6.570)	>25%
Marchini S.	2011	Italy	RT-PCR	EOC	miR-200b	Tissue	PFS	(U) 3.197 (1.417–7.213)/(M) 2.335 (0.857–6.363)
Marchini S.	2011	Italy	RT-PCR	EOC	miR-200c	Tissue	OS	(U) 0.309 (0.112–0.850)/(M) 0.244 (0.076–0.785)
Marchini S.	2011	Italy	RT-PCR	EOC	miR-200c	Tissue	PFS	(U) 0.392 (0.174–0.885)/(M) 0.419 (0.146–1.204)

Cheng H.-1	2011	USA	RT-PCR	CRC	miR-141	Blood	OS	(U) 3.80 (1.46–9.91)/(M) 1.36 (0.45–4.14)	2−ΔΔCt
Cheng H.-2	2011	USA	RT-PCR	CRC	miR-141	Blood	OS	(U) 4.83 (2.06–11.35)/(M) 3.41 (1.36–8.56)
Cheng H.-3	2011	USA	RT-PCR	CRC	miR-141	Blood	OS	(U) 3.61 (1.96–6.65)/(M) 2.40 (1.18–4.86)

Leskelä S.	2010	Spain	RT-PCR	EOC	miR-200a	FFPE	PFS	(M) 1.22 (0.57–2.58)	75% of positive cells
Leskelä S.	2010	Spain	RT-PCR	EOC	miR-200b	FFPE	PFS	(M) 1.35 (0.62–2.93)
Leskelä S.	2010	Spain	RT-PCR	EOC	miR-200c	FFPE	PFS	(M) 2.24 (1.00–5.03)
Leskelä S.	2010	Spain	RT-PCR	EOC	miR-141	FFPE	PFS	(M) 2.35 (0.98–5.59)
Leskelä S.	2010	Spain	RT-PCR	EOC	miR-429	FFPE	PFS	(M) 2.10 (0.92–4.79)
Leskelä S.	2010	Spain	RT-PCR	EOC	miR-429	FFPE	RFS	(M) 2.01 (1.11–3.66)
Leskelä S.	2010	Spain	RT-PCR	EOC	miR-429	FFPE	OS	(M) 2.08 (1.03–4.20)

Hu X.	2009	USA	RT-PCR	EOC	miR-200a	FFPE	OS	(U) 0.70 (0.03–14.29)	>11
Hu X.	2009	USA	RT-PCR	EOC	miR-200a	FFPE	PFS	(U) 0.64 (0.22–1.81)	>11

EOC: epithelial ovarian cancer; BC: breast cancer; NSCLC: nonsmall cell lung cancer; NMIBC: nonmuscle-invasive bladder cancer; GC: gastric cancer; CRC: colorectal cancer; OS: overall survival; DFS: disease-free survival; PFS: progression-free survival; RFS: recurrence- or relapse-free survival; : hazard ratio; CI: confidence interval; U: univariate analysis; M: multivariate analysis; ISH: in situ hybridization; RT-PCR: reverse transcription-polymerase chain reaction; FFPE: formalin-fixed and paraffin-embedded; TMA: tissue microarray; OS: overall survival; DFS: disease-free survival; PFS, progression-free survival; RFS: recurrence- or relapse-free survival.